Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity
The private equity owners of a trio of wound care and regenerative medicine companies said today that they’re merging Kinetic Concepts Inc., Systagenix and LifeCell into a single entity called Acelity.
Kinetic Concepts, LifeCell, Systagenix trio posts red ink in Q4
The newly formed medtech alliance comprised of Kinetic Concepts, LifeCell and Systagenix posted collective figures that put the group in the red for Q4, a recent SEC filing shows.
Kinetic Concepts touts tissue injector acquisition
Kinetic Concepts sister company LifeCell this week announced the acquisition of fat-injection devices from California medtech group TauTona.
LifeCell hopes to use the deal, the details of which were not disclosed, to expand its reconstructive and cosmetic portfolio with the fat grafting technology.
Kinetic Concepts slips in Q3, losses widen for Systagenix, LifeCell triad
Sales took a minor hit for Kinetic Concepts during its 3rd quarter 2013, reporting as part of the Centaur Guernsey companies which now includes both LifeCell and Systagenix.
KCI closes $485M buyout of Systagenix
Kinetic Concepts Inc. said it’s closed the $485 million buyout of fellow privately owned wound-care company Systagenix, which it plans to unite with its LifeCell regenerative therapies unit.
Kinetic Concepts forms trinity with LifeCell and Systagenix
Just weeks after the $485 million merger of Kinetic Concepts and Systagenix, the duo plans to merge forces with LifeCell Corp., forming a 3-headed hydra of wound care, biologics and regenerative therapies.
The new company will be run by KCI president & CEO Joe Woody, with LifeCell commercial operations chief Phil Croxford as senior vice president and "permanent leader" of LifeCell, according to a joint statement.
KCI to drop $485M on wound care company Systagenix
Kinetic Concepts Inc. said it agreed to acquire 1 of its private wound-care peers, Systagenix, for $485 million.
San Antonio, Texas-based KCI said the deal brings a large suite of complementary advanced wound care products into its portfolio.
Medtronic lands FDA clearance, plans launch for next-gen CRM lead | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) landed FDA clearance for its DF4 high-voltage right ventricular lead for use with implantable cardiac rhythm management devices.
The DF4, which builds on Medtronic’s Sprint Quattro lead, aims to help simplify the implantation process with a redesigned port and by providing visual confirmation of the lead’s connection to the device.
Delcath, Systagenix, TRIGOcare and Bio-Reference Laboratories tout new deals
Delcath Systems’ (NSDQ:DCTH) agreement with the European Institute of Oncology will launch European commercialization for the New York-based company’s Chemostat organ-targeting chemotherapy system.
Under the terms of the deal, Delcath will provide the Milan, Italy-based cancer center with logistics and clinical training support for the Chemostat system, which is awaiting full CE Mark approval.
HOLX appoints Vertex’s Stamoulis to board | Personnel Moves
Hologic Inc. (NSDQ:HOLX) appointedVertex Pharmaceuticals’ senior vice president of corporate strategy and business development to its newly expanded board of directors.
Stamoulis will also serve on the Bedford, Mass.-based company’s corporate development committee.
MassDevice Network
@MassDevice
LinkedIn
YouTube